Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Kirstine Jacobsen, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila, Cristina Teixidó, Niki Karachaliou, Martin H. Pedersen, Josep Castellví, Mónica Garzón, Carles Codony, Jordi Codony‐Servat, Ana Giménez‐Capitán, Ana Drozdowskyj, Santiago Viteri, Martin R. Larsen, Ulrik Lassen, Enriqueta Felip, Trever G. Bivona, Henrik J. Ditzel, Rafael Rosell
Nature Communications, 2017
Abstract
This research paper explore the methodology and findings associated with Nature Communications. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib 2006
- Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer 2004
- Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy 2006
- Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis 2010
- Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor 2016
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 2014
- Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer 2005
- AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) <i>In Vivo</i> 2015
- Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition 2015
- Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib 2015